Establishing the phenotype in novel acute and chronic murine models of allergic asthma.
Allergic asthma is a chronic disease of the airways, with superimposed acute inflammatory episodes which correspond to exacerbations of asthma. Two novel models of allergic asthma have been developed in mice receiving the same allergen sensitisation, but with acute or chronic allergen exposures, the latter to mimic the human situation more closely. Ovalbumin-sensitised mice were challenged by ovalbumin inhalation twice on the same day for the acute model, and 18 times over a period of 6 weeks for the chronic model. Lung function was monitored in conscious, unrestrained mice immediately after the last challenge for up to 12 h. Airway responsiveness to inhaled methacholine and serum antibody levels were determined 24 h after challenge. Bronchoalveolar inflammatory cell recruitment was determined at 2 or 24 h. Acute and chronically treated mice had similar early and late asthmatic responses peaking at 2 h and 7-8 h, respectively. IgE and IgG antibody levels, compared with naïve mice, and eosinophil infiltration, compared with naïve and saline challenge, were elevated. Airway hyperresponsiveness to methacholine was observed 24 h after challenge in both models. The acute model had higher levels of eosinophilia, whereas the chronic model showed hyperresponsiveness to lower doses of methacholine and had higher levels of total IgE and ovalbumin-specific IgG antibodies. Both novel murine models of allergic asthma bear a close resemblance to human asthma, each offering particular advantages for studying the mechanisms underlying asthma and for evaluating existing and novel therapeutic agents.
Fernandez-Rodriguez
Sofia
S
Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3NB, UK.
Ford
William R
WR
Broadley
Kenneth J
KJ
Kidd
Emma J
EJ
D000208:Acute Disease; D000280:Administration, Inhalation; D000485:Allergens / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000906:Antibodies / Q000032:analysis / Q000378:metabolism; D001249:Asthma / Q000209:etiology / Q000473:pathology*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D016085:Bronchoconstrictor Agents / Q000008:administration & dosage / Q000494:pharmacology; D002452:Cell Count; D002908:Chronic Disease; D004195:Disease Models, Animal; D006967:Hypersensitivity / Q000150:complications / Q000473:pathology*; D007073:Immunoglobulin E / Q000032:analysis / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000032:analysis / Q000096:biosynthesis; D008297:Male; D016210:Methacholine Chloride / Q000008:administration & dosage / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000276:immunology; D010641:Phenotype; D010993:Plethysmography, Whole Body; D011014:Pneumonia / Q000473:pathology; D012129:Respiratory Function Tests
D000485:Allergens; D000906:Antibodies; D016085:Bronchoconstrictor Agents; D007074:Immunoglobulin G; D016210:Methacholine Chloride; D007073:Immunoglobulin E; D010047:Ovalbumin